Literature DB >> 25919057

[The ICD-10 Symptom Rating (ISR): validation of the depression scale in a clinical sample].

Wolfram Alexis Brandt1, Thomas Loew2, Friedrich von Heymann3, Godehard Stadtmüller4, Alexander Georgi1, Michael Tischinger4, Frederik Strom4, Friederike Mutschler5, Karin Tritt6.   

Abstract

The ICD-10 Symptom Rating (ISR) 1 measures the severity of psychiatric disorders with 29 items on 5 subscales as comprehensively as possible. The following syndromes are measured: Depressive syndrome, anxiety syndrome, obsessive-compulsive syndrome, Somatoform syndrome, eating disorder syndrome as well as additional items that cover various mental syndromes, and an overall score. The study reports findings on the validity and sensitivity to change of the depression subscale (ISR-D). In a clinical sample of N=949 inpatients with depression spectrum disorders the convergent validity was determined by correlation with the Beck Depression Inventory (BDI) 3 and the subscale "depression" of the Symptom-Checklist-90-R (SCL-90-R) 4. The high correlation between the different instruments confirms the validity of the ISR-Depression Scale. The sensitivity to change of the ISR seems higher than that of the BDI and the SCL-90. Because of its economy and the good psychometric properties the ISR is recommended for use in clinical samples. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2015        PMID: 25919057     DOI: 10.1055/s-0034-1398542

Source DB:  PubMed          Journal:  Psychother Psychosom Med Psychol        ISSN: 0937-2032


  2 in total

1.  Explanatory variables for women's increased risk for mental health problems in Vietnam.

Authors:  K Megan Collier; Bahr Weiss; Amie Pollack; Trung Lam
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-08-28       Impact factor: 4.328

2.  Multimodal Treatment of Patients with Mental Symptom Load: A Pre-Post Comparison.

Authors:  Dieter Melchart; Volker Fischer; Jingzhang Dai; Stefan Hager; Lisa Dersch; Beatrice E Bachmeier
Journal:  J Clin Med       Date:  2019-10-03       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.